TY - JOUR
T1 - Longitudinal Evaluation of Chronic Rhinosinusitis Symptoms in a Population-Based Sample
AU - Sundaresan, Agnes S.
AU - Hirsch, Annemarie G.
AU - Young, Amanda J.
AU - Pollak, Jonathan
AU - Tan, Bruce K.
AU - Schleimer, Robert P.
AU - Kern, Robert C.
AU - Kennedy, Thomas L.
AU - Greene, J. Scott
AU - Stewart, Walter F.
AU - Bandeen-Roche, Karen
AU - Schwartz, Brian S.
N1 - Funding Information:
Conflicts of interest: A. S. Sundaresan has received research support from the National Institutes of Health and Teva. A. G. Hirsch, A. J. Young, J. Pollak, and K. Bandeen-Roche have received research support from the National Institutes of Health. B. K. Tan has received research support from the National Institutes of Health (grant nos. K23 DC012067 and U19 AI106683). R. P. Schleimer has received research support from the National Institutes of Health; has received consultancy fees from Intersect ENT, GlaxoSmithKline, Allakos, Merck, Sanofi, AstraZeneca/MedImmune, Genentech, and Otsuka Inc; has been a consultant for Aurasense, Biomarck, and Exicure Inc; and has stock/stock options in Allakos, Aurasense, BioMarck, and Exicure Inc. B. S. Schwartz has received research support from the National Institutes of Health, the National Institute of Allergy and Immunological Diseases. The rest of the authors declare that they have no relevant conflicts of interest.
Funding Information:
This study was supported by the Chronic Rhinosinusitis Integrative Studies Program grant from the National Institutes of Health (grant no. U19AI106683). The study sponsor did not play a role in the study design, analysis, interpretation, or writing of the report and did not take part in the decision to submit this article for publication.
Publisher Copyright:
© 2017 American Academy of Allergy, Asthma & Immunology
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Background: Chronic rhinosinusitis (CRS) is a prevalent and disabling condition of the nose and sinuses. The natural history of CRS symptoms in a general population sample has not been previously studied. Objective: In a general population–based sample from Pennsylvania, we used 2 questionnaires mailed 6 months apart to estimate the prevalence of, and identify predictors for, stability or change in symptoms over time. Methods: We mailed the baseline and 6-month follow-up questionnaires to 23,700 primary care patients and 7,801 baseline responders, respectively. We categorized nasal and sinus symptoms using European Position Paper on Rhinosinusitis (EPOS) epidemiologic criteria. We defined 6 symptom groups over time on the basis of the presence of CRS symptoms at baseline and follow-up. We performed multivariable survey logistic regression controlling for confounding variables comparing persistent versus nonpersistent, recurrent versus stable past, and incident versus never. Results: There were 4,966 responders at follow-up: 558 had persistent symptoms, 190 recurrent symptoms, and 83 new symptoms meeting EPOS criteria for CRS. The prevalence of persistent symptoms was 4.8% (95% CI, 3.8-5.8), whereas the annual cumulative incidence of new symptoms was 1.9% and of recurrent symptoms was 3.2%. More severe symptoms at baseline were associated with persistence, whereas minor symptoms, allergies, and multiple treatments were associated with the development of new symptoms. Conclusions: Less than half with nasal and sinus symptoms meeting CRS EPOS criteria in our general, regional population had symptom persistence over time, with symptom profiles at baseline and age of onset being strongly associated with stability of symptoms.
AB - Background: Chronic rhinosinusitis (CRS) is a prevalent and disabling condition of the nose and sinuses. The natural history of CRS symptoms in a general population sample has not been previously studied. Objective: In a general population–based sample from Pennsylvania, we used 2 questionnaires mailed 6 months apart to estimate the prevalence of, and identify predictors for, stability or change in symptoms over time. Methods: We mailed the baseline and 6-month follow-up questionnaires to 23,700 primary care patients and 7,801 baseline responders, respectively. We categorized nasal and sinus symptoms using European Position Paper on Rhinosinusitis (EPOS) epidemiologic criteria. We defined 6 symptom groups over time on the basis of the presence of CRS symptoms at baseline and follow-up. We performed multivariable survey logistic regression controlling for confounding variables comparing persistent versus nonpersistent, recurrent versus stable past, and incident versus never. Results: There were 4,966 responders at follow-up: 558 had persistent symptoms, 190 recurrent symptoms, and 83 new symptoms meeting EPOS criteria for CRS. The prevalence of persistent symptoms was 4.8% (95% CI, 3.8-5.8), whereas the annual cumulative incidence of new symptoms was 1.9% and of recurrent symptoms was 3.2%. More severe symptoms at baseline were associated with persistence, whereas minor symptoms, allergies, and multiple treatments were associated with the development of new symptoms. Conclusions: Less than half with nasal and sinus symptoms meeting CRS EPOS criteria in our general, regional population had symptom persistence over time, with symptom profiles at baseline and age of onset being strongly associated with stability of symptoms.
KW - Chronic rhinosinusitis
KW - Incidence
KW - Longitudinal
KW - Persistence
KW - Recurrence
UR - http://www.scopus.com/inward/record.url?scp=85033601148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85033601148&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2017.10.012
DO - 10.1016/j.jaip.2017.10.012
M3 - Article
C2 - 29133225
AN - SCOPUS:85033601148
SN - 2213-2198
VL - 6
SP - 1327-1335.e3
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 4
ER -